title: [Recent advances in bladder urothelial carcinogenesis].
abstract: Bladder cancer is the sixth cause of cancer mortality in France and prognosis of muscle-invasive tumors remains poor due to lack of effective treatments. Recent advances in molecular biology applied to tumors and results of recent genome-wide studies have brought a important impact on the understanding of bladder carcinogenesis. Main molecular alterations concern FGFR3, TP53 and HER2, and it is now possible to distinguish three subgroups of tumors according to molecular profile. This paper proposes a review of different genetic and epigenetic alterations in bladder cancer, their potential role as theranostic markers in clinical oncology and new targeted therapies according to the concept of personalized medicine.
authors.affiliation: Institut Paoli-Calmettes, service de chirurgie urologique, 13009 Marseille, France. Electronic address: pignotg@ipc.unicancer.fr.
authors.forename: Géraldine
authors.initials: G
authors.lastname: Pignot
authors.affiliation: Université Paris Descartes, institut Curie, service de génétique, unité de pharmacogénomique, 75005 Paris, France.
authors.forename: Constance
authors.initials: C
authors.lastname: le Goux
authors.affiliation: Université Paris Descartes, institut Curie, service de génétique, unité de pharmacogénomique, 75005 Paris, France.
authors.forename: Ivan
authors.initials: I
authors.lastname: Bieche
mesh_terms: D044127:Epigenesis, Genetic; D016147:Genes, Tumor Suppressor; D018734:Genes, erbB-2; D016158:Genes, p53; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D053842:Microsatellite Instability; D058990:Molecular Targeted Therapy / Q000379:methods; D009154:Mutation; D009361:Neoplasm Invasiveness; D051498:Receptor, Fibroblast Growth Factor, Type 3 / Q000235:genetics; D001749:Urinary Bladder Neoplasms / Q000235:genetics* / Q000473:pathology / Q000628:therapy
chemical_list: C496365:FGFR3 protein, human; D051498:Receptor, Fibroblast Growth Factor, Type 3
keywords: Bladder cancer; Carcinogenesis; Carcinogenèse; Marqueurs moléculaires; Molecular markers; Targeted therapies; Thérapies ciblées; Tumeur de vessie